share_log

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

Morgan Stanley Maintains Equal-Weight on Cytek Biosciences, Lowers Price Target to $7

摩根士丹利維持對Cytek Biosciences的同等權重,將目標股價下調至7美元
Benzinga ·  2023/11/09 09:02

Morgan Stanley analyst Tejas Savant maintains Cytek Biosciences (NASDAQ:CTKB) with a Equal-Weight and lowers the price target from $8 to $7.

摩根士丹利分析師Tejas Savant維持Cytek Biosciences(納斯達克股票代碼:CTKB)的權重持平,並將目標股價從8美元下調至7美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論